Aurora, CO Clinical Trials Report — July 2026

Aurora participants should act quickly if they match a study involving vascular disease, cardiovascular health, lupus nephritis, or related conditions: 44 recruiting trials are expected to close within the next 90 days. Of those, 8 accept healthy volunteers. Aurora also opened 18 new trials in July, up from 15 in May, bringing the city’s active recruiting total to 975 trials across 311 research facilities.

Closing windows for local participants

Enrollment may end sooner than the projected closing date if a study reaches its participant target. The largest groups of closing-soon trials concern vascular and cardiovascular health, but several other conditions are represented:

• Vascular diseases (2 trials)
• Endothelial dysfunction (2 trials)
• Transgenderism (2 trials)
• Vascular stiffness (2 trials)
• Cardiovascular diseases (2 trials)
• Lupus nephritis (2 trials)
• Bleeding, autonomic dysfunction, arthritis, and cervical cancer (1 trial each)

Healthy volunteers should also check eligibility now rather than waiting. Eight of these closing-soon studies accept healthy participants, while 117 healthy-volunteer trials are recruiting in Aurora overall. Medical screening, age requirements, medication restrictions, and visit schedules differ by study.

July brings late-stage drug studies and new local options

Drug studies were the largest category among July’s openings, with 9 new drug trials. Behavioral studies accounted for 5, while other study types accounted for 3. One combination-product study and one device study also opened. The new-trial mix includes heart failure, acute myeloid leukemia, chronic obstructive pulmonary disease, cystic fibrosis, diabetes, and sexual-assault resistance programming.

• NCT07720271 is Novo Nordisk’s Phase 3 AMAZE 9 study of once-daily zenagamtide tablets for adults with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07684820 is a Phase 2 Expedition Therapeutics study of EXPD-101/FXS7553 for people with COPD. It plans to enroll 600 participants and compares two doses of the study drug with placebo over 52 weeks.
• NCT07728188 is an AbbVie Phase 3 study for adults with relapsed or refractory multiple myeloma. It compares injected etentamig plus oral pomalidomide with standard therapies and plans to enroll 520 participants.
• NCT07714239, sponsored by the VA Office of Research and Development, tests pharmacist-assisted adjustment of heart-failure medicines after hospitalization. The study expects 585 participants.
• NCT07714252 is a VA-sponsored study of a virtual nurse and social-worker palliative-care team for Veterans with heart failure or COPD. It plans to enroll 420 participants.
• NCT07696338, the REACT trial, examines early airway-clearance approaches for people with cystic fibrosis, including hypertonic saline and dornase alfa studies. Planned enrollment is 405 participants.

Among July’s sponsors, the University of Colorado, Denver leads with 5 new trials, followed by the VA Office of Research and Development with 3. Other sponsors include Aquestive Therapeutics, Expedition Therapeutics, Icahn School of Medicine at Mount Sinai, ML Bio Solutions, AbbVie, and Novo Nordisk. The new-trial pool includes 7 industry-sponsored studies, 7 categorized as other, and 4 federally sponsored studies.

Where Aurora has the greatest research access

Aurora’s trial activity is concentrated around the Anschutz medical campus, children’s research programs, university hospitals, cancer centers, and the VA. Children’s Hospital Colorado is the largest listed site, while the University of Colorado Anschutz Medical Campus and other University of Colorado facilities provide broad adult and specialty-care options.

• Children’s Hospital Colorado (157 trials)
• University of Colorado Anschutz Medical Campus (91 trials)
• University of Colorado (75 trials)
• UCHealth University of Colorado Hospital (55 trials)
• University of Colorado Hospital (51 trials)
• University of Colorado Cancer Center (36 trials)
• University of Colorado Denver (27 trials)
• Rocky Mountain Regional VA Medical Center, Aurora (25 trials)
• Rocky Mountain Cancer Centers-Aurora and Research Site (23 trials each)

Children’s Hospital Colorado is especially relevant for families seeking pediatric studies, while the Anschutz campus, university hospitals, and University of Colorado Cancer Center offer dense options in oncology, heart and lung disease, metabolic conditions, and other specialties. Veterans may find additional opportunities through the Rocky Mountain Regional VA Medical Center.

Eligibility for children, older adults, and healthy volunteers

Of the 18 new July trials, 7 include children and 14 include older adults. Two are female-only, and none is male-only. These figures describe the eligibility categories reported for the new openings; each study has its own age, health, and participation requirements.

Healthy volunteers have opportunities beyond the closing-soon group: three of July’s 18 new trials accept healthy participants, and 117 recruiting studies in Aurora are open to healthy volunteers overall. People without a diagnosed condition should review these studies promptly, particularly those with flexible schedules or interest in contributing to drug, behavioral, or other research.

Other Colorado cities to consider

Participants willing to travel can search beyond Aurora. Denver has 10 nearby recruiting trials listed, while Carbondale, Edwards, Englewood, Fort Collins, Louisville, Boulder, and Pueblo each have 1. Denver is the most substantial nearby alternative in the current data, but specialty availability may differ by condition and eligibility.

July’s 18 new openings follow 17 in February, 13 in March, 15 in April, 23 in May, and 15 in June. As new studies continue to appear and closing dates approach, Aurora residents should contact research sites early to confirm availability, screening steps, and whether travel to another Colorado city could expand their options.